Interactive Investor
>>

Hemogenyx Pharmaceuticals (LSE:HEMO) Share Price

HEMO

Hemogenyx Pharmaceuticals

UK company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

Bid

-

Ask

-

Last Traded

-

Chg

-

-

XLON

-

Updated: -

Research

News & analysis

Regulatory news

Loading...

Times are shown in BST, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

Company Profile

Hemogenyx Pharmaceuticals PLC and its subsidiary is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy. Its two distinct products include an immunotherapy product for patient conditioning, the CDX bi-specific antibody, and a cell therapy product for BM/HSC transplantation, the HuPHEC.Hemogenyx Pharmaceuticals PLC is a preclinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma.

LSE:HEMO

GB00BYX3WZ24

GBX

Loading...

Loading Comparison

Latest HEMO News

HEMO Regulatory News